Global Chronic Renal Failure Therapeutics Market 2019-2023

The global chronic renal failure therapeutics market size will grow by USD 3.17 billion during 2019-2023. The chronic renal failure therapeutics market report provides a detailed analysis of the market by product (antihypertensive therapeutics, antianemia therapeutics, and others) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors, including Amgen Inc., AstraZeneca Plc, Bayer AG, F. Hoffmann-La Roche Ltd., and Pfizer Inc.

A few of the key findings this chronic renal failure therapeutics market analysis report are summarized below

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from the chronic renal failure therapeutics market report.

Get a FREE sample now!

Global Chronic Renal Failure Therapeutics Market Overview

The global chronic renal failure therapeutics market witnessed significant growth in both the developing and developed countries across the globe in recent years. Cardiovascular and metabolic disorders are significant risk factors for chronic renal failure. The rising prevalence of these risk factors is contributing to the significant increase in the incidence of chronic renal disease. According to the CDC, adults with chronic renal disease are having a higher risk of mortality. The majority of the demand for the treatment of this condition is from the geriatric population in the US, Europe, and Asia.  This rising prevalence of chronic renal failure will subsequently augment the growth prospects of the global chronic renal failure therapeutics market during the forecast period.

Moreover, the development of novel hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors will also fuel chronic renal failure therapeutics market growth. Oral HIF-PH inhibitors such as roxadustat and vadadustat have minimal cardiovascular side-effects compared with ESA injections. The oral administration of HIF-PH drugs is optimal for patients who are not undergoing hemodialysis. These factors are increasing the preference for these drugs, which will contribute to the growth of the global chronic renal failure therapeutics market. As a result of these factors, the market will register a CAGR of almost 5% during 2019-2023.

Top Chronic Renal Failure Therapeutics Companies Covered in this Market Research Report

The global chronic renal failure therapeutics market is fragmented. The chronic renal failure therapeutics market report provides an analysis of the market’s competitive landscape and offers information on the products offered by various companies. This will help clients in improving their market positions. It also provides a detailed analysis of the upcoming chronic renal disease, therapeutics market trends, and challenges that will influence market growth. The research will help companies in creating effective strategies to leverage the upcoming market growth opportunities.

The report offers a detailed analysis of many leading chronic renal failure therapeutics companies, including:

• Amgen Inc.
• AstraZeneca Plc
• Bayer AG
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc.

Chronic Renal Failure Therapeutics Market Segmentation Based on Product

• Antihypertensive therapeutics
• Antianemia therapeutics
• Others

Antihypertensive therapeutics held the largest market share in 2018 and will maintain its leading position until 2023. Hypertension and diabetes account for 72% of the causes of chronic renal failure. Therefore, most of the current treatments, such as ACE and ARB inhibitors, calcium channel blockers, and diuretics, for chronic renal failure are targeted to control hypertension and blood sugar levels. These drugs are cost-effective and have been included in health insurance schemes. As a result, the use of these drugs will remain prevalent over the forecast period.       

Chronic Renal Failure Therapeutics Market Segmentation Based on Geographic Region

• Asia
• Europe
• North America
• ROW

North America was the largest market shareholder in 2018. The growing prevalence of chronic renal failure, among the rising geriatric population, especially in the US and Canada, has been contributing to the growth of the market in the region. This coupled with the availability of reimbursement schemes, and new drug approvals will enable the market to retain its leading position in 2023.

Key Highlights of the Global Chronic Renal Failure Therapeutics Market Forecast Report for the Period 2019-2023

• CAGR of the market during the forecast period 2019-2023
• Detailed information on factors that will accelerate the growth of the chronic renal failure therapeutics market during the next five years
• Precise estimation of the global chronic renal failure therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the chronic renal failure therapeutics industry across Asia, Europe, North America, and ROW
• A thorough analysis of the market’s competitive landscape and detailed information on several vendors
• Comprehensive details of factors that will challenge the growth of chronic renal failure therapeutics companies

We can help! Our analysts can customize the chronic renal failure therapeutics market research report to meet your requirements. Get in touch